Skip to main content

Summary

Eligibility
for people ages 6 years and up
Location
at San Francisco, California and other locations
Dates
study started
Principal Investigator

Description

Summary

Fibrodysplasia ossificans progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in abnormal bone formation in muscles, tendons, and ligaments. Flare-ups begin early in life and may occur spontaneously or after soft tissue trauma, vaccinations, or influenza infections. Recurrent flare-ups progressively restrict movement by locking joints leading to cumulative loss of function and disability. Mouse models of FOP have demonstrated the ability of retinoic acid receptor (RAR) gamma agonists to prevent heterotopic ossification (HO) following injury. The purpose of the study is to evaluate whether palovarotene, an RAR gamma agonist, will prevent HO during and following a flare-up in subjects with FOP.

Official Title

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Details

The primary objective is to evaluate the ability of different doses of palovarotene to prevent HO at the flare-up site in subjects with FOP as assessed by plain radiographs.

This is a Phase 2, multi-center, randomized, double-blind, sponsor-unblinded, placebo-controlled study. Two cohorts of subjects will be randomized into different dosing regimens of palovarotene for a 6-week (42 days) treatment period. The study will consist of three periods:

  1. A Screening period to occur within 7 days of a distinct flare-up. The first dose of study drug will be taken within 7 days of the flare-up initiation.
  2. A double-blind treatment period of 6 weeks (42 days) duration.
  3. A follow-up period of 6 weeks (42 days) duration.

An initial cohort (Cohort 1) of subjects will be randomly assigned 3:1 to either palovarotene or placebo daily for 42 days. Subjects randomized to palovarotene in Cohort 1 will receive an initial daily dose of 10 mg for 14 days followed by 5 mg daily for 28 days.

In Cohort 2, new FOP subjects meeting all inclusion/exclusion criteria will be randomly assigned 3:3:2 to two dose regimens of palovarotene (10 mg for 14 days and 5 mg for 28 days; 5 mg for 14 days and 2.5 mg for 28 days) or placebo daily for 42 days. Doses will be weight-adjusted and subjects randomized within three weight-range categories (20 to <40 kg, 40 to <60 kg, and ≥60 kg).

Subjects completing the study and still meeting eligibility requirements will be given the opportunity to enroll into an open-label extension study.

Keywords

Fibrodysplasia Ossificans Progressiva Intervention study Clinical trial Phase 2 Efficacy and safety Heterotopic ossification Flare-up Palovarotene Retinoic acid receptor agonist Retinoic acid receptor gamma agonist Clementia Myositis Ossificans Progressiva Munchmeyer's Disease FOP

Eligibility

You can join if…

Open to people ages 6 years and up

  • Written, signed, and dated informed subject/parent consent or age-appropriate assent.
  • Subjects clinically diagnosed with classic Fibrodysplasia Ossificans Progressiva(FOP).
  • Symptomatic onset of a distinct flare-up within 7 days of Study Day 1 (start of study drug) and defined by the presence of at least two of six of the following symptoms:pain, soft tissue swelling, decreased range of motion, stiffness, redness, and warmth.Flare-up must be confirmed by the physician at the Screening visit.
  • Flare-up is at an appendicular area (upper or lower extremity), abdomen, or chest; and subject has received, is receiving, or is willing to receive treatment per standard of care, which may or may not include oral prednisone (2 mg/kg PO to a maximum dose of 100 mg daily) for 4 days.
  • Abstinent or using two highly effective forms of birth control.
  • Subjects must be accessible for treatment and follow-up. Subjects living at distant locations from the investigational site must be able and willing to travel to a site for the initial and all follow-up visits.

You CAN'T join if...

  • Weight <20 kg.
  • Intercurrent non-healed fracture at any location.
  • Complete immobilization of joint at site of flare-up.
  • The inability of the subject to undergo imaging assessments using plain radiographs.
  • If currently using vitamin A or beta carotene, multivitamins containing vitamin A or beta carotene, or herbal preparations, fish oil, and unable or unwilling to discontinue use of these products for the duration of the study.
  • Exposure to synthetic oral retinoids in the past 30 days prior to Screening (signature of the informed consent).
  • Concurrent treatment with tetracycline due to the potential increased risk of pseudotumor cerebri.
  • History of allergy or hypersensitivity to retinoids or lactose.
  • Concomitant medications that are inhibitors or inducers of CYP450 3A4 activity.
  • Amylase or lipase>1.5x above the upper limit of normal or with a history of chronic pancreatitis.
  • Elevated aspartate aminotransferase or alanine aminotransferase>2.5x the upper limit of normal.
  • Fasting triglycerides>400 mg/dL with or without therapy.

Locations

  • University of Pennsylvania, Center for Research in FOP & Related Disorders
    Philadelphia, Pennsylvania, 19104, United States
  • The Royal National Orthopaedic Hospital, Brockley Hill
    Stanmore, Middlesex, HA7 4LP, United Kingdom
  • Hôpital Necker-Enfants Malades, Department of Genetics
    Paris, France

Details

Status
in progress, not accepting new patients
Start Date
Sponsor
Clementia Pharmaceuticals Inc.
Links
Website for the International FOP Association
Click here for more information about this study: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With FOP
ID
NCT02190747
Phase
Phase 2
Lead Scientist
Edward Hsiao
Study Type
Interventional
Last Updated
July 18, 2016